Fundz

R3 Vascular reported raising $72.5 Million in an initial SEC Form D filing

PRIVATESep 12, 2024Late filing, first sale Apr 26, 2024

Amount Raised

$72.5 Million

$72.5 Million sold, per SEC Form D (first sale Apr 26, 2024)

Round Type

Venture

Mountain ViewManufacturingBiotechnology

Quick answer

R3 Vascular raised $72.5 Million in a funding round, dated April 26, 2024. R3 Vascular is based in Mountain View, California, United States.

How much did R3 Vascular raise?
R3 Vascular raised $72.5 Million in a funding round on April 26, 2024.
What does R3 Vascular do?
R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds.
Where is R3 Vascular based and how big is it?
R3 Vascular is based in Mountain View, California, United States.
Who are the decision-makers at R3 Vascular?
Fundz holds 2 contacts at R3 Vascular. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Manufacturing and Biotechnology around the same time

Companies in the same sectors as R3 Vascular that raised within 45 days of this round, from Fundz verified event records.

  • DIH Holding US raised $3.3M (Seed) on June 7, 2024.
  • Advanced Medicine Partners raised $32M (Debt Financing) on June 6, 2024.
  • Scimplify raised $5M (Funding Round) on June 5, 2024.
  • Nucleus RadioPharma raised an undisclosed amount (Series A) on June 5, 2024.
  • Packwise raised $1M (Seed) on May 31, 2024.
  • NUTRUMAMI raised $488K (Pre-Seed) on May 30, 2024.

Who to call at R3 Vascular, and when

A new round usually means R3 Vascular is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day R3 Vascular raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at R3 Vascular, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at R3 Vascular. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

R3 Vascular

Location

Mountain View, California, United States

About

R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds. These are designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory and anti-proliferative result of sirolimus, but ‘disappearing’ over time as the vessel heals.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment R3 Vascular raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for R3 Vascular's next move

See what Strategic adds

R3 Vascular raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.